公开(公告)号：US11718643B2

公开(公告)日：2023-08-08

申请号：US14441129

申请日：2013-11-11

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Jean-Luc Maloisel ,  Gustav Rodrigo ,  Bjorn Noren ,  Virendra Kumbhar

IPC: B01D15/32 ,  B01D15/36 ,  B01D15/38 ,  B01J20/26 ,  B01J20/28 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32 ,  B01J41/20 ,  C07K1/16 ,  C07K1/36 ,  C07K16/00 ,  C07K16/06 ,  G01N33/544

CPC classification number: C07K1/165 ,  B01D15/327 ,  B01D15/363 ,  B01D15/3847 ,  B01J20/265 ,  B01J20/286 ,  B01J20/289 ,  B01J20/28016 ,  B01J20/3204 ,  B01J20/3208 ,  B01J20/3219 ,  B01J20/3251 ,  B01J20/3253 ,  B01J20/3255 ,  B01J20/3285 ,  B01J41/20 ,  C07K1/36 ,  C07K16/00 ,  C07K16/065 ,  G01N33/544 ,  B01D15/3809 ,  B01D15/3885 ,  B01J2220/52 ,  B01J2220/80 ,  B01D15/363 ,  B01D15/327

Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five- or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.

公开(公告)号：US10815269B2

公开(公告)日：2020-10-27

申请号：US16115756

申请日：2018-08-29

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Gustav Rodrigo ,  Bjorn Noren ,  Virendra Kumbhar

IPC: B01D15/32 ,  B01D15/36 ,  B01D15/38 ,  B01J20/26 ,  B01J20/28 ,  B01J20/286 ,  B01J20/289 ,  B01J20/32 ,  B01J41/20 ,  C07K1/16 ,  G01N33/544 ,  C07K16/00 ,  C07K16/06 ,  C07K1/36

Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five-or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.

公开(公告)号：US20190241608A1

公开(公告)日：2019-08-08

申请号：US16386628

申请日：2019-04-17

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Ola Lind ,  Bjorn Noren ,  Ronnie Palmgren

IPC: C07K1/22 ,  C07K16/06 ,  C07K16/00

CPC classification number: C07K1/22 ,  C07K1/145 ,  C07K16/00 ,  C07K16/065 ,  C07K2317/55

Abstract: The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.

公开(公告)号：US10266563B2

公开(公告)日：2019-04-23

申请号：US15308327

申请日：2015-06-04

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Ola Lind ,  Bjorn Noren ,  Ronnie Palmgren

IPC: C07K1/22 ,  C07K16/00 ,  C07K16/06 ,  C07K1/14

Abstract: The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.

公开(公告)号：US20170051010A1

公开(公告)日：2017-02-23

申请号：US15308327

申请日：2015-06-04

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Ola Lind ,  Bjorn Noren ,  Ronnie Palmgren

IPC: C07K1/22 ,  C07K16/00

CPC classification number: C07K1/22 ,  C07K1/145 ,  C07K16/00 ,  C07K16/065 ,  C07K2317/55

Abstract: The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.

Abstract translation: 本发明涉及在用于纯化目标分子的色谱方法（优选单克隆抗体mAb）中通过使用具有薄的外层和核心功能化的专门设计的色谱珠来去除大污染物如病毒的方法 具有吸附mAb或其部分的配体。

公开(公告)号：US10465153B2

公开(公告)日：2019-11-05

申请号：US15037539

申请日：2014-11-26

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Jean-Luc Maloisel ,  Tobias Soderman ,  Ola Lind

IPC: C12H1/056 ,  B01D15/00 ,  B01J20/32 ,  B01J20/28 ,  C08F251/00

Abstract: The invention discloses a separation matrix with a porous solid support and a plurality of polyvinylpyrrolidone (PVP) polymer chains covalently attached to the solid support. The polyvinylpyrrolidone polymer chains are either vinylpyrrolidone homopolymer chains or copolymer chains which comprise at least 70 mol % vinylpyrrolidone monomer residues and less than 2 mol % negatively charged monomer residues.

公开(公告)号：US20190111419A1

公开(公告)日：2019-04-18

申请号：US16090609

申请日：2017-03-30

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Jean-Luc Maloisel ,  Tobias Söderman ,  Ola Lind ,  Ida Eklind

IPC: B01J47/02 ,  B01J39/07 ,  B01J39/19 ,  B01J39/26 ,  B01J41/07 ,  B01J41/13 ,  B01J41/20 ,  C07K1/18 ,  B01D15/36 ,  B01D15/38 ,  B01D15/32

Abstract: The invention discloses a separation matrix for purification of biomacromolecules, comprising a plurality of particles (1) having a core region (2) and a shell region (3), wherein: a) said shell region is accessible to a target biomacromolecule; b) said core region is less accessible to the target biomacromolecule than the shell region; and c) the core region comprises a grafted polymer comprising residues of at least one polymerizable monomer.

公开(公告)号：US20180127460A1

公开(公告)日：2018-05-10

申请号：US15564232

申请日：2016-04-04

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Martin Hall ,  Karolina Busson ,  Jean-Luc Maloisel ,  Helena Skoglar

IPC: C07K1/18 ,  B01D15/36 ,  B01D15/38 ,  B01D15/34 ,  C12N9/64 ,  C07K14/755 ,  C07K16/00 ,  C07K14/765 ,  C07K14/47 ,  B01J41/20

CPC classification number: C07K1/18 ,  A61K35/16 ,  A61K38/00 ,  A61K38/36 ,  A61K38/4846 ,  B01D15/34 ,  B01D15/363 ,  B01D15/3847 ,  B01J41/20 ,  C07K14/472 ,  C07K14/755 ,  C07K14/765 ,  C07K16/00 ,  C12N9/6424 ,  C12N9/644 ,  C12Y304/21022

Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of plasmaproteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.

公开(公告)号：US20160367966A1

公开(公告)日：2016-12-22

申请号：US15120845

申请日：2015-02-18

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Jean-Luc Maloisel ,  Karolina Busson ,  Karol Lacki ,  Bjorn Noren ,  Helena Skoglar

IPC: B01J20/32 ,  B01J20/28 ,  B01D15/20 ,  B01D15/30 ,  C12N1/20 ,  B01D15/12 ,  C07K1/22 ,  C07K14/765 ,  C07K14/77 ,  B01J20/286 ,  B01D15/36

CPC classification number: B01J20/3293 ,  B01D15/125 ,  B01D15/203 ,  B01D15/305 ,  B01D15/363 ,  B01J20/28019 ,  B01J20/286 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3248 ,  B01J20/327 ,  B01J20/3278 ,  C07K1/22 ,  C07K14/765 ,  C07K14/77 ,  C12N1/20

Abstract: The invention discloses a separation matrix for purification of biological particles, comprising a plurality of particles having a porous core entity and a porous shell entity covering the core entity, wherein the core entity comprises at least 50 micromole/ml primary amines present on covalently attached ligands displaying at least two primary amines per ligand and the shell entity comprises less than 20 micromole/ml primary amines The invention further discloses a method of purifying biological particles and a method of manufacturing a separation matrix.

Abstract translation: 本发明公开了一种用于纯化生物颗粒的分离基质，其包含多个具有多孔核心实体和覆盖核心实体的多孔壳体的颗粒，其中核心实体包含共价连接的配体上存在的至少50微摩尔/ 每个配体显示至少两个伯胺，壳体包含少于20微摩尔/ ml伯胺本发明还公开了一种纯化生物颗粒的方法和一种制备分离基质的方法。

公开(公告)号：US10662261B2

公开(公告)日：2020-05-26

申请号：US15937428

申请日：2018-03-27

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Mattias Algotsson ,  Lars C. Andersson ,  Eggert Brekkan ,  Lee Hedemyr ,  Jean-Luc Maloisel ,  Ronnie Palmgren

IPC: C08B37/00 ,  B01J20/289 ,  B01J20/32 ,  C07C237/10 ,  C07C323/60 ,  B01J20/281

Abstract: The present invention relates to dimeric pentadentate chelators with exceptionally strong binding of metal ions, for detection, immobilization and purification of biomolecules. Dimeric chelators offer a cooperativity of binding of two adjacent immobilized metal ions simultaneously to a histidine-tagged biomolecule, which gives advantageous properties regarding strength of binding compared to a corresponding monomer chelator. In addition, a dimer increases the selectivity (ease of separation) against non-tagged biomolecules with low metal-ion affinity.